Benzo[B]pyrano[3,2-H]acridin-2-one cinnamate compounds, a process for their preparation and pharmaceutical compositions containing them

摘要

Benzo pyarano[3,2-h]acridin-7-one cinnamate compounds (I) and their enantiomers, diastereoisomers, hydrates, solvates, acids, bases or addition salts are new. Benzo pyarano[3,2-h]acridin-7-one cinnamate compounds of formula (I) and their enantiomers, diastereoisomers, hydrates, solvates, acids, bases or addition salts are new. X, Y 1H, halo, OH, (1-6C) alkoxy, nitro, CN, (1-6C) alkyl (optionally substituted by one or more OH or halo), (2-6C) alkenyl or -NRaRb; either R-a, R-b : H or (1-6C) alkyl; or N-R-aR-b : a monocyclic or 5-7-membered heterocycle optionally having a second heteroatom of O or N in the cyclic system; Z : O or NR-c; R-c : H, (1-6C) alkyl, aryl or aryl-(1-6C)alkyl; Ar : (hetero)aryl; R 1, R 3, R 4H or (1-6C) alkyl; R 2H, (1-6C) alkyl, OR-a or NR-aR-b; R 5OR-c, NR-cR-d, W 1-C(W 2)-U 1-V 1, W-a-C(W 2)-W 3-T 1 or -Z-CO-CH=CHAr; W-a, W 3O or NR-c; W 2O; U 1(1-8C) alkylene or (2-8C) alkenylene; V 1H, (hetero) aryl, OR, CO 2R-c, COR-c, CON-aaR-bb, NR-aaR-bb, N(R-c)-CO 2R-cc or N(R-c)COR-cc; R-cc : R-c; either R-aa, R-bb : R-a, R-b or aryl-(1-6C)alkyl; or N-R-aaR-bb : N-R-aR-b; and T 1H, (1-6C) alkyl or (2-6C) alkenyl, aryl or aryl-(1-6C) alkyl (all optionally substituted by OR-c or NR-aaR-bb). where the aryl is phenyl or naphthyl optionally substituted by one or more substituents of (1-6C) alkyl (optionally substituted by one or more OH or halo), OH, halo, carboxy, NO 2, NH 2, or mono- or di-(1-6C) alkylamino, where the alkyl moiety is (1-6C) alkoxy, (1-6C) acyl or (1-6C) alkylcarbonyloxy; and the heteroaryl is 5-12-membered (monocyclic, aromatic or bicyclic with aromatic ring(s)), and has 1, 2 or 3 heteroatoms of O, N or S, and optionally substituted by one or more groups of halo, (1-6C) alkyl optionally substituted by one or more OH, halo, (1-6C) alkoxy or NH 2 optionally substituted by one or two (1-6C)alkyl. [Image] ACTIVITY : Cytostatic. MECHANISM OF ACTION : None given.